Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00006433|
Recruitment Status : Unknown
Verified November 2001 by National Center for Research Resources (NCRR).
Recruitment status was: Recruiting
First Posted : November 6, 2000
Last Update Posted : June 24, 2005
Purpose: The purpose of this protocol is to evaluate the combination of Doxil chemotherapy and heat treatment for recurrent breast cancer located on the chestwall following mastectomy. This protocol also includes patients with metastatic breast cancer who have not had mastectomy but have advanced tumor remaining within the breast. Doxil is the drug adriamycin (also called doxorubicin) encapsulated in liposomes, which coats the drug with a small amount of lipid (fat). This chemotherapy is in a newer form which can be better delivered to the tumor tissue without causing as much systemic toxicity. We are combining heat treatment with this drug in an effort to further increase the delivery of drug to the tumor, which may give an increased tumor response.
Methods: The patients will be treated with chemotherapy followed by heat treatment. This will be given for 6 cycles approximately every 4 weeks. For the first cycle patients will need to be hospitalized 3 days for measurement of blood levels of drug as well as some additional radiology studies which will help us to determine whether the drug is preferentially distributed within tumor.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: Doxil Procedure: heat treatment||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Study Start Date :||January 2000|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006433
|Contact: Janye Blivin, R.N., M.S.N.||1-919-660-2174|
|United States, North Carolina|
|Radiation Oncology, Duke University Medical Center||Recruiting|
|Durham, North Carolina, United States, 21170|
|Contact: Janye Blivin, RN, MSN 919-660-2174|
|Principal Investigator: Leonard R. Prosnitz, MD|
|Principal Investigator:||Leonard R. Prosnitz, M.D.|